Intellia Therapeutics(NTLA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 . L L L PRESS RELEASE Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-end - Strong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead ...